Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: J Neurooncol. 2021 Oct 1;155(1):93–100. doi: 10.1007/s11060-021-03847-y

TABLE 2.

Association between clinical and demographic characteristics and endocrine outcomes in patients with pediatric medulloblastoma, 1997–2016

Hypothyroidism Adrenal Insufficiency Growth Hormone Deficiency
Present
(n=35) *
Absent
(n=78) *
P-value Present
(n=20) *
Absent
(n=94) *
P-value Present
(n=71) *
Absent
(n=36) *
P-value
Mean age at diagnosis, yr (SD) 8.22 (4.29) 7.40 (3.54) 0.29 7.76 (3.82) 7.36 (3.58) 0.66 7.00 (3.17) 7.95 (4.18) 0.19
Sex, n(%) 0.82 0.17 0.96
 Male 24 (68.6) 56 (71.8) 17 (85.0) 65 (69.2) 51 (71.8) 26 (72.2)
 Female 11 (31.4) 22 (28.2) 3 (15.0) 29 (30.9) 20 (28.2) 10 (27.8)
Race/Ethnicity, n(%) 0.18 0.28 0.08
 Non-Hispanic White 18 (51.4) 27 (34.6) 5 (25.0) 42 (44.7) 33 (46.5) 13 (36.1)
 Hispanic 13 (37.1) 28 (35.9) 10 (50.0) 31 (33.0) 26 (36.6) 11 (30.6)
 Non-Hispanic Black 3 (8.6) 14 (18.0) 4 (20.0) 12 (12.8) 8 (11.3) 5 (13.9)
 Non-Hispanic Other 1 (2.9) 9 (11.5) 1 (5.0) 9 (9.6) 4 (5.6) 7 (19.4)
CSI radiation dose, n(%) 0.19 0.29 0.82
 <30 Gy 21 (60.0) 58 (74.4) 12 (60.0) 68 (72.3) 48 (67.6) 25 (71.4)
 ≥30 Gy 14 (40.0) 20 (25.6) 8 (40.0) 26 (27.7) 23 (32.4) 10 (28.6)
Treatment Protocol, n(%) 0.35 0.30 0.04
 SJMB 96 7 (20.0) 14 (18.0) 2 (10.0) 20 (21.3) 11 (15.5) 4 (11.4)
 SJMB 03 17 (48.6) 35 (44.9) 9 (45.0) 43 (45.7) 37 (52.1) 14 (40.0)
 COG AA9961 8 (22.9) 13 (16.7) 7 (35.0) 14 (14.9) 14 (19.7) 5 (14.3)
 SJMB 12 0 (0.0) 8 (10.3) 1 (5.0) 7 (7.5) 6 (8.5) 3 (8.6)
 Other 3 (8.6) 8 (10.3) 1 (5.0) 10 (10.6) 3 (4.2) 9 (25.7)
*

Number of cases and controls may not combine to a total of 118 patients since patients were excluded if there was insufficient laboratory data to determine their endocrinopathy status.

SD, standard deviation; CSI, craniospinal irradiation; SJMB, St. Jude Medulloblastoma; COG, Children’s Oncology Group